Teleflex (NYSE:TFX) Given New $191.00 Price Target at Morgan Stanley

Teleflex (NYSE:TFX) had its target price decreased by stock analysts at Morgan Stanley from $275.00 to $191.00 in a research report issued on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the medical technology company’s stock. Morgan Stanley’s target price indicates a potential upside of 40.11% from the stock’s current price.

TFX has been the topic of several other reports. Citizens Jmp cut shares of Teleflex from an “outperform” rating to a “market perform” rating in a research note on Thursday, February 27th. Needham & Company LLC reiterated a “hold” rating on shares of Teleflex in a research report on Monday, December 16th. Truist Financial reduced their target price on Teleflex from $200.00 to $149.00 and set a “hold” rating for the company in a research report on Monday. Royal Bank of Canada lowered Teleflex from an “outperform” rating to a “sector perform” rating and decreased their target price for the stock from $220.00 to $155.00 in a research note on Friday, February 28th. Finally, Bank of America downgraded Teleflex from a “neutral” rating to an “underperform” rating and dropped their price target for the company from $235.00 to $140.00 in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $182.63.

Teleflex Stock Performance

NYSE:TFX opened at $136.32 on Wednesday. The business’s fifty day moving average is $171.92 and its 200 day moving average is $202.22. The firm has a market cap of $6.33 billion, a price-to-earnings ratio of 27.10, a PEG ratio of 1.73 and a beta of 1.16. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.39 and a current ratio of 2.42. Teleflex has a 52-week low of $128.55 and a 52-week high of $249.90.

Teleflex (NYSE:TFX) last posted its earnings results on Thursday, February 27th. The medical technology company reported $3.89 earnings per share for the quarter, beating analysts’ consensus estimates of $3.86 by $0.03. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. The business had revenue of $795.40 million during the quarter, compared to analyst estimates of $813.24 million. Research analysts predict that Teleflex will post 13.98 EPS for the current year.

Institutional Trading of Teleflex

Several hedge funds and other institutional investors have recently bought and sold shares of TFX. Apollon Wealth Management LLC lifted its holdings in shares of Teleflex by 3.7% in the 3rd quarter. Apollon Wealth Management LLC now owns 1,524 shares of the medical technology company’s stock worth $377,000 after acquiring an additional 55 shares during the last quarter. SRS Capital Advisors Inc. lifted its stake in Teleflex by 0.3% in the third quarter. SRS Capital Advisors Inc. now owns 19,587 shares of the medical technology company’s stock worth $4,844,000 after purchasing an additional 60 shares during the last quarter. Janney Montgomery Scott LLC boosted its position in Teleflex by 0.4% during the third quarter. Janney Montgomery Scott LLC now owns 15,332 shares of the medical technology company’s stock valued at $3,792,000 after buying an additional 65 shares during the period. Tokio Marine Asset Management Co. Ltd. grew its stake in shares of Teleflex by 4.5% during the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 1,517 shares of the medical technology company’s stock valued at $375,000 after buying an additional 66 shares during the last quarter. Finally, HighTower Advisors LLC increased its holdings in shares of Teleflex by 1.7% in the third quarter. HighTower Advisors LLC now owns 3,998 shares of the medical technology company’s stock worth $986,000 after buying an additional 66 shares during the period. Hedge funds and other institutional investors own 95.62% of the company’s stock.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.